Our Focus
We use a patient-centric approach to identify and develop transformative medicines for the treatment of severe rare diseases. Our lead product candidate, apraglutide, is a next generation, long-acting synthetic GLP-2 analog which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.


Learning to Live with the Hidden Scars of SBS-IF
We’re proud to stand with and listen to patients who experience #shortbowelsyndrome with #intestinalfailure (SBS-IF).
Latest News
December 9, 2022
VectivBio Announces Results of Extraordinary General Meeting
-Wouter Joustra Elected to the Board of Directors BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter
November 16, 2022
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which